<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Heavy menstrual bleeding — DGRefHelp Drafts</title>
  <link rel="stylesheet" href="../assets/site.css" />
</head>
<body>
  <div class="container">
    <div class="header">
      <div class="brand">
        <h1><a href="../index.html">DGRefHelp drafts</a> / Heavy menstrual bleeding</h1>
        <div class="sub">National pathway (NHS Scotland CfSD) + NICE NG88 → DGRefHelp first draft (D&amp;G). Includes required referral-letter info.</div>
      </div>
      <div class="badges">
        <div class="badge">Mode: quick</div>
        <div class="badge">Last updated: 2026‑02‑11</div>
      </div>
    </div>

    <div class="grid">
      <div class="card">
        <div class="card-hd">
          <div class="tabs" data-tabs>
            <button class="tab" role="tab" data-tab="evidence" aria-selected="true">Evidence</button>
            <button class="tab" role="tab" data-tab="draft" aria-selected="false">DGRefHelp draft</button>
            <button class="tab" role="tab" data-tab="refs" aria-selected="false">References</button>
          </div>
          <div class="copybar">
            <button class="btn" data-copy-target="#draftText">Copy draft</button>
            <button class="btn" data-copy-target="#evidenceText">Copy evidence</button>
          </div>
        </div>

        <div class="card-bd">
          <div class="panel active" role="tabpanel" data-panel="evidence">
            <div id="evidenceText" class="section">
              <h3>Evidence summary (triangulated)</h3>

              <div class="callout">
                <strong>Related pages</strong>
                <div class="small">
                  <ul>
                    <li><a href="./abnormal-uterine-bleeding.html">Abnormal uterine bleeding</a> (if bleeding is irregular/IMB/PCB rather than cyclical HMB).</li>
                    <li><a href="./postcoital-bleeding.html">Postcoital bleeding</a> (if bleeding is specifically after sex).</li>
                    <li><a href="./symptomatic-colposcopy.html">Symptoms suggestive of cervical cancer (PCB/discharge) — referral &amp; colposcopy</a> (if cervix/vagina/vulva looks suspicious or symptoms concerning).</li>
                    <li><a href="./postmenopausal-bleeding.html">Postmenopausal bleeding</a> (if established postmenopausal).</li>
                  </ul>
                </div>
              </div>

              <div class="callout ok">
                <strong>Key decision points (for a GP-facing pathway page)</strong>
                <ul>
                  <li>Start with <strong>impact on quality of life</strong> (NG88), then assess for <strong>structural</strong> vs <strong>histological</strong> pathology risk.</li>
                  <li><strong>Baseline tests</strong>: FBC for all; TSH only if clinically indicated (NG88 + NHS Scotland pathway).</li>
                  <li><strong>First-line treatment</strong> for many people with no obvious structural cause: LNG‑IUS, or (if unsuitable/declined) tranexamic acid / NSAIDs / CHC / cyclical progestogen (NG88; mirrored in the national pathway).</li>
                  <li><strong>Imaging/investigation choices</strong>: offer ultrasound when uterus is palpable abdominally / pelvic mass suspected / exam inconclusive (NG88); consider hysteroscopy and targeted biopsy when endometrial pathology risk is higher (NG88).</li>
                </ul>
              </div>

              <h4>NHS Scotland CfSD HMB pathway (v1)</h4>
              <ul>
                <li>Pragmatic “one page” primary care algorithm, explicitly including: FBC; TSH only if indicated; and high‑risk features prompting concern for endometrial pathology (e.g., persistent intermenstrual/postcoital bleeding, PCOS with obesity, tamoxifen use, age &gt;45 with increased bleeding).</li>
                <li>Includes treatment options commonly used in primary care and flags when to consider ultrasound and/or referral for hysteroscopy/biopsy/colposcopy/gynae.</li>
              </ul>

              <h4>NICE NG88 (HMB)</h4>
              <ul>
                <li>NG88 emphasises that the aim is to improve quality of life (not just quantify blood loss).</li>
                <li>FBC for all; do not test thyroid function unless symptomatic for thyroid disease; consider coagulation disorder testing if HMB since menarche with personal/family history.</li>
                <li>Investigation selection is guided by symptoms/risk: hysteroscopy for suspected submucosal fibroid/polyp/endometrial pathology; ultrasound for possible larger fibroids or pelvic mass; TVUS preferred for suspected adenomyosis.</li>
              </ul>

              <div class="callout warn">
                <strong>Local variation to highlight (D&amp;G)</strong>
                <ul>
                  <li>If D&amp;G uses a local “direct-to” service (e.g., community gynaecology, one‑stop clinic, hysteroscopy triage) or specific ultrasound access arrangements, that should be explicit in “Who to refer” and “Referral letter: required info”.</li>
                  <li>Where secondary care triage tools are used (e.g., BMI, age bands, treatment failures, suspected mass), the pathway should state the <strong>metrics needed on the referral</strong>.</li>
                </ul>
              </div>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="draft">

            <div class="callout" style="margin-bottom:12px">
              <strong>Copy/paste HTML for Right Decisions accordion sections</strong>
              <div class="small">These snippets contain section content only (no internal headings). Paste each into the matching accordion section.</div>
              <div style="height:10px"></div>
              <div class="copybar" style="justify-content:flex-start">
                <button class="btn" data-copy-target="#htmlBackground">Copy Background HTML</button>
                <button class="btn" data-copy-target="#htmlAssessment">Copy Assessment HTML</button>
                <button class="btn" data-copy-target="#htmlPCM">Copy Primary care mgmt HTML</button>
                <button class="btn" data-copy-target="#htmlRefer">Copy Who to refer HTML</button>
                <button class="btn" data-copy-target="#htmlNotRefer">Copy Who not to refer HTML</button>
                <button class="btn" data-copy-target="#htmlRefs">Copy References HTML</button>
              </div>

              <details style="margin-top:10px">
                <summary class="small" style="cursor:pointer">Show HTML snippets</summary>

                <h4 style="margin:12px 0 6px">Background (HTML)</h4>
                <pre id="htmlBackground">&lt;ul&gt;
  &lt;li&gt;Heavy menstrual bleeding (HMB) is defined by the woman’s perception that bleeding is excessive and affects quality of life.&lt;/li&gt;
  &lt;li&gt;Assess for features suggesting &lt;strong&gt;structural&lt;/strong&gt; causes (fibroids/polyp/mass) or &lt;strong&gt;histological&lt;/strong&gt; risk (endometrial pathology).&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Assessment (primary care) (HTML)</h4>
                <pre id="htmlAssessment">&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;History:&lt;/strong&gt; bleeding pattern; impact on life; pelvic pain/pressure; persistent intermenstrual bleeding; postcoital bleeding; fertility wishes; contraception; previous treatment; comorbidities.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;High‑risk features (endometrial pathology consideration):&lt;/strong&gt; persistent intermenstrual or postcoital bleeding; PCOS with obesity; age &amp;gt;45 with increased bleeding; tamoxifen use; treatment failure.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Examination:&lt;/strong&gt; pelvic exam if symptoms/risk suggest pelvic mass/uterine abnormality or before LNG‑IUS; consider speculum if postcoital bleeding/discharge.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Tests:&lt;/strong&gt; FBC for all; TSH only if clinically indicated; consider coagulation disorder testing if HMB since menarche plus personal/family history of bleeding disorder.&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Primary care management (HTML)</h4>
                <pre id="htmlPCM">&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;If low risk of structural/histological abnormality:&lt;/strong&gt; start treatment without initial imaging/invasive investigation.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Most effective option&lt;/strong&gt; (when appropriate): LNG‑IUS.&lt;/li&gt;
  &lt;li&gt;If LNG‑IUS declined/unsuitable: consider &lt;strong&gt;tranexamic acid&lt;/strong&gt; during menses; &lt;strong&gt;NSAIDs&lt;/strong&gt;; &lt;strong&gt;combined hormonal contraception&lt;/strong&gt; (&lt;strong&gt;without a pill‑free week&lt;/strong&gt; as per the national pathway); or &lt;strong&gt;cyclical oral progestogen&lt;/strong&gt; (e.g. days 5–26).&lt;/li&gt;
  &lt;li&gt;Consider depot progestogen contraception (e.g., DMPA/Sayana Press) where appropriate.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;When to consider ultrasound:&lt;/strong&gt; uterus palpable abdominally, pelvic mass suspected, or exam inconclusive/difficult.&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Who to refer (HTML)</h4>
                <pre id="htmlRefer">&lt;p&gt;&lt;strong&gt;Refer/seek specialist assessment&lt;/strong&gt; when structural or histological abnormality is suspected, or when treatment fails.&lt;/p&gt;

&lt;ul&gt;
  &lt;li&gt;&lt;strong&gt;Histological abnormality suspected&lt;/strong&gt; (high‑risk features or treatment failure): consider referral for hysteroscopy ± endometrial sampling (service dependent).&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Structural abnormality suspected&lt;/strong&gt; (uterus palpable abdominally / pelvic mass): arrange ultrasound and refer as indicated.&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Scan findings:&lt;/strong&gt; suspicious pelvic mass → urgent gynae referral; fibroids &amp;gt;3 cm → gynae referral (first‑line medical options may still help while awaiting review).&lt;/li&gt;
  &lt;li&gt;&lt;strong&gt;Postcoital bleeding / cervix concern&lt;/strong&gt;: consider colposcopy pathway as locally indicated; state speculum findings clearly.&lt;/li&gt;
&lt;/ul&gt;

&lt;p class=&quot;small&quot;&gt;&lt;strong&gt;Referral letter: required information (triage metrics)&lt;/strong&gt;&lt;/p&gt;
&lt;ul&gt;
  &lt;li&gt;Age, BMI (if known), parity; smoking status if relevant to treatment choice.&lt;/li&gt;
  &lt;li&gt;Bleeding pattern: duration; flooding/clots; intermenstrual bleeding; postcoital bleeding; impact on quality of life.&lt;/li&gt;
  &lt;li&gt;Pelvic symptoms: pain/pressure; urinary/bowel symptoms; any mass symptoms.&lt;/li&gt;
  &lt;li&gt;Current contraception; fertility wishes.&lt;/li&gt;
  &lt;li&gt;Risk factors: PCOS + obesity; tamoxifen; anticoagulation; family/personal bleeding disorder history.&lt;/li&gt;
  &lt;li&gt;Treatments tried and duration (LNG‑IUS / TXA / NSAIDs / CHC / progestogens) and response.&lt;/li&gt;
  &lt;li&gt;Examination findings (including speculum) and FBC result; TSH if done for clinical indication.&lt;/li&gt;
  &lt;li&gt;If imaging performed: ultrasound report details (fibroid size/location, endometrial appearance, adnexal findings).&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">Who not to refer (HTML)</h4>
                <pre id="htmlNotRefer">&lt;ul&gt;
  &lt;li&gt;Many women with HMB and no related symptoms suggesting structural/histological abnormality can start first‑line medical management in primary care.&lt;/li&gt;
&lt;/ul&gt;</pre>

                <h4 style="margin:12px 0 6px">References (HTML)</h4>
                <pre id="htmlRefs">&lt;ol&gt;
  &lt;li&gt;NHS Scotland Centre for Sustainable Delivery: NHS Scotland Heavy Menstrual Bleeding Pathway v1 (review noted Feb 2024; review date April 2024). https://www.nhscfsd.co.uk/media/osfjcpxe/nhs-scotland-heavy-menstrual-bleeding-pathway-v1.pdf (retrieved 2026‑02‑08)&lt;/li&gt;
  &lt;li&gt;NICE NG88: Heavy menstrual bleeding: assessment and management (last reviewed 19 Dec 2024). https://www.nice.org.uk/guidance/ng88 (retrieved 2026‑02‑08)&lt;/li&gt;
&lt;/ol&gt;</pre>
              </details>
            </div>

            <div id="draftText" class="section">
              <h3>Heavy menstrual bleeding</h3>

              <div class="callout" style="margin:10px 0 12px">
                <strong>Related pages</strong>
                <div class="small">
                  <ul>
                    <li><a href="./abnormal-uterine-bleeding.html">Abnormal uterine bleeding</a></li>
                    <li><a href="./postcoital-bleeding.html">Postcoital bleeding</a></li>
                    <li><a href="./symptomatic-colposcopy.html">Symptoms suggestive of cervical cancer (PCB/discharge) — referral &amp; colposcopy</a></li>
                    <li><a href="./postmenopausal-bleeding.html">Postmenopausal bleeding</a></li>
                  </ul>
                </div>
              </div>

              <h4>Background</h4>
              <ul>
                <li>Heavy menstrual bleeding (HMB) is defined by the woman’s perception that bleeding is excessive and affects quality of life.</li>
                <li>Assess for features suggesting <strong>structural</strong> causes (fibroids/polyp/mass) or <strong>histological</strong> risk (endometrial pathology).</li>
              </ul>

              <h4>Assessment (primary care) — collapsible</h4>
              <ul>
                <li><strong>History:</strong> bleeding pattern; impact on life; pelvic pain/pressure; persistent intermenstrual bleeding; postcoital bleeding; fertility wishes; contraception; previous treatment; comorbidities.</li>
                <li><strong>High‑risk features (endometrial pathology consideration):</strong> persistent intermenstrual or postcoital bleeding; PCOS with obesity; age &gt;45 with increased bleeding; tamoxifen use; treatment failure.</li>
                <li><strong>Examination:</strong> pelvic exam if symptoms/risk suggest pelvic mass/uterine abnormality or before LNG‑IUS; consider speculum if postcoital bleeding/discharge.</li>
                <li><strong>Tests:</strong> FBC for all; TSH only if clinically indicated; consider coagulation disorder testing if HMB since menarche plus personal/family history of bleeding disorder.</li>
              </ul>

              <h4>Primary care management</h4>
              <ul>
                <li><strong>If low risk of structural/histological abnormality:</strong> start treatment without initial imaging/invasive investigation.</li>
                <li><strong>Most effective option</strong> (when appropriate): LNG‑IUS.</li>
                <li>If LNG‑IUS declined/unsuitable: consider <strong>tranexamic acid</strong> during menses; <strong>NSAIDs</strong>; <strong>combined hormonal contraception</strong> (<strong>without a pill‑free week</strong> as per the national pathway); or <strong>cyclical oral progestogen</strong> (e.g. days 5–26).</li>
                <li>Consider depot progestogen contraception (e.g., DMPA/Sayana Press) where appropriate.</li>
                <li><strong>When to consider ultrasound:</strong> uterus palpable abdominally, pelvic mass suspected, or exam inconclusive/difficult.</li>
              </ul>

              <h4>Who to refer</h4>
              <p class="small">Key principle: include the metrics secondary care needs for triage (risk factors + what has been tried).</p>

              <ul>
                <li><strong>Histological abnormality suspected</strong> (high‑risk features or treatment failure): consider referral for hysteroscopy ± endometrial sampling (service dependent).</li>
                <li><strong>Structural abnormality suspected</strong> (uterus palpable abdominally / pelvic mass): arrange ultrasound and refer as indicated.</li>
                <li><strong>Scan findings:</strong> suspicious pelvic mass → urgent gynae referral; fibroids <strong>&gt;3 cm</strong> → gynae referral (first‑line medical options may still help while awaiting review).</li>
                <li><strong>Postcoital bleeding / cervix concern</strong>: consider colposcopy pathway as locally indicated; state speculum findings clearly.</li>
              </ul>

              <h4>Referral letter: required information (triage metrics)</h4>
              <ul>
                <li>Age, BMI (if known), parity; smoking status if relevant to treatment choice.</li>
                <li>Bleeding pattern: duration; flooding/clots; intermenstrual bleeding; postcoital bleeding; impact on quality of life.</li>
                <li>Pelvic symptoms: pain/pressure; urinary/bowel symptoms; any mass symptoms.</li>
                <li>Current contraception; fertility wishes.</li>
                <li>Risk factors: PCOS + obesity; tamoxifen; anticoagulation; family/personal bleeding disorder history.</li>
                <li>Treatments tried and duration (LNG‑IUS / TXA / NSAIDs / CHC / progestogens) and response.</li>
                <li>Examination findings (including speculum) and FBC result; TSH if done for clinical indication.</li>
                <li>If imaging performed: ultrasound report details (fibroid size/location, endometrial appearance, adnexal findings).</li>
              </ul>

              <h4>Who not to refer</h4>
              <ul>
                <li>Many women with HMB and no related symptoms suggesting structural/histological abnormality can start first‑line medical management in primary care.</li>
              </ul>

              <h4>Local agreement needed (drafting-site only)</h4>
              <ul>
                <li><label><input type="checkbox" disabled /> Confirm local referral routes/services for suspected endometrial pathology (direct-to hysteroscopy clinic? general gynae?).</label></li>
                <li><label><input type="checkbox" disabled /> Confirm whether D&amp;G uses any specific thresholds for referral by fibroid size/location beyond the national pathway’s “&gt;3 cm” prompt.</label></li>
                <li><label><input type="checkbox" disabled /> Confirm any local contraindications/preferences for CHC/progestogens (e.g., VTE-risk wording) that should be stated explicitly.</label></li>
                <li><label><input type="checkbox" disabled /> Confirm whether D&amp;G expects ultrasound before referral in certain circumstances (or whether secondary care orders imaging).</label></li>
              </ul>
            </div>
          </div>

          <div class="panel" role="tabpanel" data-panel="refs">
            <div class="section">
              <h3>References</h3>
              <ol>
                <li>NHS Scotland Centre for Sustainable Delivery: NHS Scotland Heavy Menstrual Bleeding Pathway v1 (review noted Feb 2024; review date April 2024). <a href="https://www.nhscfsd.co.uk/media/osfjcpxe/nhs-scotland-heavy-menstrual-bleeding-pathway-v1.pdf">https://www.nhscfsd.co.uk/media/osfjcpxe/nhs-scotland-heavy-menstrual-bleeding-pathway-v1.pdf</a> (retrieved 2026‑02‑08)</li>
                <li>NICE NG88: Heavy menstrual bleeding: assessment and management (last reviewed 19 Dec 2024). <a href="https://www.nice.org.uk/guidance/ng88">https://www.nice.org.uk/guidance/ng88</a> (retrieved 2026‑02‑08)</li>
              </ol>
            </div>
          </div>

        </div>
      </div>
    </div>
  </div>

  <script src="../assets/site.js"></script>
</body>
</html>
